Alterations of the AML1 transcription factor in human leukemia

Seminars in Cell and Developmental Biology

Volumn 11, Issue 5, 2000, Pages 347-360

  Downing, James R ^a   Higuchi, Masakazu ^a   Lenny, Noel ^a   Yeoh, Allen Eng Juh ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

Acute lymphoblastic leukemia; Acute myeloid leukemia; Chromosomal translocations; Histone deacetylase; Transcriptional repression

Indexed keywords

CORE BINDING FACTOR; HISTONE DEACETYLASE; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR AML 1; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; CHROMOSOME REARRANGEMENT; CHROMOSOME TRANSLOCATION; HEMATOPOIESIS; HUMAN; LEUKEMIA; LEUKEMOGENESIS; MOLECULAR CLONING; NONHUMAN; PROTEIN ANALYSIS; PROTEIN DEFECT; REGULATORY MECHANISM; REVIEW; TRANSCRIPTION REGULATION;

EID: 0034489606     PISSN: 10849521     EISSN: None     Source Type: Journal    
DOI: 10.1006/scdb.2000.0183     Document Type: Article

References (96)

1. Core-binding factor: A central player in hematopoiesis and leukemia
2. The AML1-ETO chimaeric transcription factor in acute myeloid leukaemia: Biology and clinical significance
3. Role of the transcription factor AML-1 in acute leukemia and hematopoietic differentiation
4. t(8;21) breakpoints on chromosome 21 in acute myeloid leukemia are clustered within a limited region of a single gene, AML1
5. Identification of breakpoints in t(8;21) acute myelogenous leukemia and isolation of a fusion transcript, AML1/ETO, with similarity to Drosophila segmentation gene, runt
6. Transcriptionally active chimeric gene derived from the fusion of the AML1 gene and a novel gene on chromosome 8 in t(8;21) leukemic cells
7. The t(8;21) translocation in acute myeloid leukemia results in production of an AML1-MTG8 fusion transcript
8. The 3;21 translocation in myelodysplasia results in a fusion transcript between the AML1 gene and the gene for EAP, a highly conserved protein associated with the Epstein-Barr virus small RNA EBER I
9. Generation of the AML1-EVI-1 fusion gene in the t(3;21) (q26;q22) causes blastic crisis in chronic myelocytic leukemia
10. The partner gene of AML1 in t(16;21) myeloid malignancies is a novel member of the MTG8 (ETO) family
11. Fusion of the TEL gene on 12p13 to the AML1 gene on 21q22 in acute lymphoblastic leukemia
12. The t(12;21) of acute lymphoblastic leukemia results in a tel-AML1 gene fusion
13. CBFA2(AML1) translocations with novel partner chromosomes in myeloid leukemias: Association with prior therapy
14. Fusion between transcription factor CBF beta/PEBP2 beta and a myosin heavy chain in acute myeloid leukemia
15. Biochemical and biophysical properties of the core-binding factor alpha2 (AML1) DNA-binding domain
16. Cloning and characterization of subunits of the T-cell receptor and murine leukemia virus enhancer core-binding factor
17. Molecular cloning and characterization of PEBP2 beta, the heterodimeric partner of a novel Drosophila runt-related DNA binding protein PEBP2 alpha
18. Leukemogenesis by CBF oncoproteins
19. Inter-action and functional cooperation of the leukemia-associated factors AML1 and p300 in myeloid cell differentiation
20. Nuclear receptor coactivator ACTR is a novel histone acetyltransferase and forms a multimeric activation complex with P/CAF and CBP/p300
21. What's up and down with histone deacetylation and transcription?
22. ALY, a context-dependent coactivator of LEF-1 and AML-1, is required for TCRalpha enhancer function
23. A WW domain-containing yes-associated protein (YAP) is a novel transcriptional co-activator
24. Negative regulation of granulocytic differentiation in the myeloid precursor cell line 32Dc13 by ear-2, a mammalian homolog of Drosophila seven-up, and a chimeric leukemogenic gene, AML1/ETO
25. A mechanism of repression by acute myeloid leukemia-1, the target of multiple chromosomal translocations in acute leukemia
26. Groucho-dependent and -independent repression activities of Runt domain proteins
27. Transcriptional repression by AML1 and LEF-1 is mediated by the TLE/Groucho corepressors
28. The extracellular signal-regulated kinase pathway phosphorylates AML1, an acute myeloid leukemia gene product, and potentially regulates its transactivation ability
29. A large variety of alternatively spliced and differentially expressed mRNAs are encoded by the human acute myeloid leukemia gene AML1
30. An acute myeloid leukemia gene, AML1, regulates hemopoietic myeloid cell differentiation and transcriptional activation antagonistically by two alternative spliced forms
31. A novel transcript encoding an N-terminally truncated AML1/PEBP2 alphaB protein interferes with transactivation and blocks granulocytic differentiation of 32Dc13 myeloid cells
32. PEBP2 alpha B/mouse AML1 consists of multiple isoforms that possess differential transactivation potentials
33. Intrinsic transcriptional activation-inhibition domains of the polyomavirus enhancer binding protein 2/core binding factor α subunit revealed in the presence of the β subunit
34. The mammalian basic helix loop helix protein HES-1 binds to and modulates the transactivating function of the runt-related factor Cbfa1
35. Identification of homeotic target genes in Drosophila melanogaster including nervy, a proto-oncogene homologue
36. The AML1-MTG8 leukemic fusion protein forms a complex with a novel member of the MTG8(ETO/CDR) family, MTGR1
37. Identification of two transcripts of AML1/ETO-fused gene in t(8;21) leukemic cells and expression of wild-type ETO gene in hematopoietic cells
38. Expression of AML1 and ETO transcripts in hematopoietic cells
39. ETO, fusion partner in t(8;21) acute myeloid leukemia, represses transcription by interaction with the human N-CoR/mSin3/HDAC1 complex
40. ETO, a target of t(8;21) in acute leukemia, interacts with the N-CoR and mSin3 corepressors
41. Aberrant recruitment of the nuclear receptor corepressor-histone deacetylase complex by the acute myeloid leukemia fusion partner ETO
42. The ETO protein disrupted in t(8;21)-associated acute myeloid leukemia is a corepressor for the promyelocytic leukemia zinc finger protein
43. The MYND motif is required for repression of basal transcription from the multidrug resistance 1 promoter by the t(8;21) fusion protein
44. The AML1/ETO fusion protein blocks transactivation of the GM-CSF promoter by AML1B
45. Synergistic up-regulation of the myeloid-specific promoter for the macrophage colony-stimulating factor receptor by AML1 and the t(8;21) fusion protein may contribute to leukemogenesis
46. The t(8;21) fusion product. AML-1-ETO, associates with C/EBP-alpha, inhibits C/EBP-alpha-dependent transcription, and blocks granulocytic differentiation
47. The t(8;21) fusion protein interferes with AML-1B-dependent transcriptional activation
48. Functional domains of the t(8;21) fusion protein, AML-1/ETO
49. Inhibitors of histone deacetylase relieve ETO-mediated repression and induce differentiation of AML1-ETO leukemia cells
50. The AML1/ETO fusion protein activates transcription of BCL-2
51. Growth inhibition and induction of differentiation of t(8;21) acute myeloid leukemia cells by the DNA-binding domain of PEBP2 and the AML1/MTG8(ETO)-specific antisense oligonucleotide
52. Characterization of the ETO and AML1-ETO proteins involved in 8;21 translocation in acute myelogenous leukemia
53. Embryonic lethality and impairment of haematopoiesis in mice heterozygous for an AML1-ETO fusion gene
54. Expression of a knockedin AML1-ETO leukemia gene inhibits the establishment of normal definitive hematopoiesis and directly generates dysplastic hematopoietic progenitors
55. Persistence of the 8;21 translocation in patients with acute myeloid leukemia type M2 in long-term remission
56. Persistence of multipotent progenitors expressing AML1/ETO transcripts in long-term remission patients with t(8;21) acute myelogenous leukemia
57. Expression of AML1/MTG8 transcripts in clonogenic cells grown from bone marrow of patients in remission of acute myeloid leukaemia with t(8;21)
58. Preleukemic AML1/ETO-expressing hematopoietic stem cells in acute myelogenous leukemia with 8;21 chromosomal translocation; evidence for multistep leukemogenesis
59. Fatal myeloproliferation, induced in mice by TEL/PDGFbetaR expression, depends on PDGFbetaR tyrosines 579/581
60. Germ line transmission of a conditional AML1-ETO allele allows cre-mediated induction of AL-ETO expression in multipotential hematopoietic progenitors in adult mice and results in the immortalization of myeloid cells
61. Deletion of a DNA polymerase β gene segment in T cells using cell type-specific gene targeting
62. Fourth international workshop on chromosomes in leukemia 1982: Translocation (8;21) (q22;q22) in acute nonlymphocytic leukemia
63. Associations between morphology, karyotype, and clinical features in myeloid leukemias
64. Chromosomal abnormalities in 478 children with acute myeloid leukemia: Clinical characteristics and treatment outcome in a cooperative pediatric oncology group study - POG 8821
65. C-kit mutations in core binding factor leukemias
66. Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype
67. The importance of diagnostic cytogenetics on outcome in AML: Analysis of 1,612 patients enrolled into the MRC AML 10 trial
68. The t(12;21) translocation converts AML-1B from an activator to a repressor of transcription
69. Functional characterization of ETV6 and ETV6/CBFA2 in the regulation of the MCSFR proximal promoter
70. Both TEL and AML-1 contribute repression domains to the t(12;21) fusion protein
71. Three distinct domains in TEL-AML1 are required for transcriptional repression of the IL-3 promoter
72. Deletion of the short arm of chromosome 12 is a secondary event in acute lymphoblastic leukemia with t(12;21)
73. Yolk sac angiogenic defect and intra-embryonic apoptosis in mice lacking the Ets-related factor TEL
74. The TEL/ETV6 gene is required specifically for hematopoiesis in the bone marrow
75. Dual functions of the AML1/Evi-1 chimeric protein in the mechanism of leukemogenesis in t(3;21) leukemias
76. The t(3;21) fusion product, AML1/Evi-1, interacts with Smad3 and blocks transforming growth factor-beta-mediated growth inhibition of myeloid cells
77. Interaction and functional cooperation of PEBP2/CBF with Smads. Synergistic induction of the immunoglobulin germline Calpha promoter
78. Smad and AML proteins synergistically confer transforming growth factor beta1 responsiveness to human germ-line IgA genes
79. The AML1/Evi-1 fusion protein in the t(3;21) translocation exhibits transforming activity on Rat1 fibroblasts with dependence on the Evi-1 sequence
80. Human AML1/MDS1/EVI1 fusion protein induces an acute myelogenous leukemia (AML) in mice: A model for human AML
81. The Evi-1 proto-oncogene encodes a transcriptional repressor activity associated with transformation
82. Haploinsufficiency of CBFA2 causes familial thrombocytopenia with propensity to develop acute myelogenous leukaemia
83. AML1, the target of multiple chromosomal translocations in human leukemia, is essential for normal fetal liver hematopoiesis
84. The CBFbeta subunit is essential for CBFalpha2 (AML1) function in vivo
85. Studies of a familial platelet disorder
86. Inherited platelet-storage pool deficiency associated with a high incidence of acute myeloid leukaemia
87. A fatal myeloproliferative syndrome in a family with thrombocytopenia and platelet dysfunction
88. The missing bone
89. AML1 haploinsufficiency, gene dosage, and the predisposition to acute leukemia
90. Hapleinsufficiency of AML1/cBFAβ affects the embryonic generation of mouse hematopoietic stem cells
91. Biallelic and heterozygous point mutations in the runt domain of the AML1/PEBP2alphaB gene associated with myeloblastic leukemias
92. 0 AML
93. AML1 gene amplification: A novel finding in childhood acute lymphoblastic leukemia
94. Identification of murine CBF alpha1, a runt domain transcription factor, as a putative Myc collaborator in T cell lymphoma
95. Leukaemia disease genes: Large-scale cloning and pathway predictions
96. Risks of leukemia and solid tumors in individuals with Down's syndrome